NCT06087627 - A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

June 6, 2026

Study Completion Date

December 28, 2026

Conditions

Prurigo Nodularis

Interventions

DRUG

Dupilumab SAR231893 (REGN668)

Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)

Trial Locations (11)

12203

RECRUITING

Investigational site number: 001, Berlin

13507

RECRUITING

Investigational Site Number: 002, Berlin

14467

RECRUITING

Investigational Site Number: 022, Potsdam

14469

RECRUITING

Investigational Site Number: 024, Potsdam

22391

RECRUITING

Investigational Site Number: 007, Hamburg

40219

RECRUITING

Investigational Site Number: 004, Düsseldorf

52349

RECRUITING

Investigational Site Number: 005, Düren

55128

RECRUITING

Investigational Site Number: 031, Mainz

56626

RECRUITING

Investigational Site Number: 013, Adernach

09117

RECRUITING

Investigational Site Number: 023, Chemnitz

04371

RECRUITING

Investigational Site Number: 016, Leipzig